RT Journal Article SR Electronic T1 Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP p878 VO 38 IS Suppl 55 A1 Decramer, Marc A1 Maltais, Francois A1 Feldman, Gregory A1 Brooks, Jean A1 Willits, Lisa A1 Harris, Stephanie A1 Crater, Glenn YR 2011 UL https://publications.ersnet.org//content/38/Suppl_55/p878.abstract AB Introduction: GSK573719 is an inhaled LAMA with sustained 24-hour activity under development as a once-daily therapy for COPD.Objective: To evaluate the dose response of GSK573719 in patients with COPD.Methods: This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group study evaluating GSK573719 administered once daily via a novel single-step activation dry powder inhaler in patients with COPD (FEV1 of ≥35 and ≤70% predicted). The primary endpoint was morning pre-dose (trough) FEV1 after 28 days of treatment.Results: All doses of GSK573719 significantly increased trough FEV1 compared with placebo, with improvement ranging from 150 to 168mL (p<0.001). All doses significantly increased 0–6 hour weighted mean FEV1 compared with placebo with differences ranging from 113 to 211mL (p<0.001). Additionally, all doses demonstrated significant improvements over placebo in serial FEV1 at each measured time point over 24 hours (p≤0.038). Reductions in albuterol use and improvements in FVC were also noted for all doses. All doses were well tolerated.Conclusion: Once-daily dosing with GSK573719 provides clinically significant and sustained improvement in lung function and is well tolerated over 24 hours in patients with COPD.Funded by GSK (AC4113589; NCT01030965)